Italia markets close in 6 hours 19 minutes

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
67,08+0,05 (+0,07%)
Alla chiusura: 04:00PM EDT
67,30 +0,22 (+0,33%)
Preborsa: 05:05AM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente67,03
Aperto66,59
Denaro67,07 x 400
Lettera67,11 x 400
Min-Max giorno66,36 - 67,18
Intervallo di 52 settimane65,90 - 87,87
Volume8.264.467
Media Volume7.193.293
Capitalizzazione83,647B
Beta (5 anni mensile)0,20
Rapporto PE (ttm)14,91
EPS (ttm)4,50
Prossima data utili25 apr 2024
Rendimento e dividendo (futuro)3,08 (4,59%)
Data ex dividendo14 mar 2024
Stima target 1A83,88
  • GlobeNewswire

    Global CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032

    PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic

  • GlobeNewswire

    Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant from Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States

    LAFAYETTE, Colo., July 20, 2023 (GLOBE NEWSWIRE) -- The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant program. CDA Foundation will disperse the grant to qualifying tax-exempt organizations to contact diagnosed but untreated patients with hepatitis C virus (HCV) or hepatitis B virus (HBV) infection to bring them back into care. Despite the availability of existing tr